Two‐year changes of macular choroidal thickness in response to 0.01% atropine eye drops: Results from the myopia outcome study of atropine in children ( <scp>MOSAIC</scp> ) clinical trial
Myopic participants treated with 0.01% atropine exhibited stable ChT over 2 years, whereas the placebo group showed consistent thinning. The effect of atropine 0.01% on ChT was only partially explained by axial length and SER changes, indicating a direct effect of atropine treatment on the choroid.
Authors
- James Loughman (ORCID: https://orcid.org/0000-0003-3130-8991)
- Gareth Lingham (ORCID: https://orcid.org/0000-0002-8957-0733)
- Emmanuel Kobia‐Acquah (ORCID: https://orcid.org/0000-0002-5955-7992)
- Daniel Ian Flitcroft
Institutions
- The University of Western Australia (AU)
- Technological University Dublin (IE)
Publication Details
- Journal
- Acta Ophthalmologica
- Published
- 2024-12-29
- DOI
- https://doi.org/10.1111/aos.17429
- Citations
- 4
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.15